Have you been following the developments for Leukine? That is not chemotherapy, but it's one of the agents Dr. Myers likes to use at times when first line chemo no longer works.
Dr. Robert Leibowitz was still talking about a combination of agents several years ago. He described them as a cocktail. They included: taxotere, emcyt, decadron and carboplatin, as I recall it. I'm not sure what his current preferences are.
Satraplatin looked highly promising based on the hype and some early studies, but it failed in its major trial. However, apparently some work is still going forward, and it might prove to have a useful role at some point.
Interim results for Provenge, the immune therapy, are soon to be reported, and there is reason to hope these results will be convincing enough to warrant FDA approval. The FDA has said it will approve Provenge if the interim results are statistically significant. Dr. Eric Small, a prominent prostate cancer researcher from UCSF, was the lead author on a recent paper or two indicating that Provenge led to much longer survival for patients who had had taxotere (docetaxel).